Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines

Govindan,Sindhu  Valiyaveedan; Kulsum,Safeena; Pandian,Ramanan   Somasundara; Das,Debashish; Seshadri,Mukund; Hicks,Wesley; Kuriakose,Moni  Abraham; Suresh,Amritha

doi:10.3892/mmr.2015.3768

Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines

Authors:
- Sindhu Valiyaveedan Govindan
- Safeena Kulsum
- Ramanan Somasundara Pandian
- Debashish Das
- Mukund Seshadri
- Wesley Hicks
- Moni Abraham Kuriakose
- Amritha Suresh
View Affiliations

Affiliations: Integrated Head and Neck Oncology Research Program, DSRG‑5, Mazumdar Shaw Centre for Translational Research, Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, Karnataka 560099, India, GROW Laboratory, Narayana Nethralaya, Narayana Health, Bangalore, Karnataka 560099, India, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo NY 14263, USA, Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, Buffalo NY 14263, USA
Published online on: May 12, 2015 https://doi.org/10.3892/mmr.2015.3768
Pages: 3025-3032

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to chemotherapy leading to poor outcome and survival remains a challenge for developing strategies for therapeutic interventions in all types of cancer, including head and neck cancer. In vitro chemoresistant cell line models are an indispensable resource towards delineating the mechanisms involved in drug resistance/response and for the development of novel drugs. Current treatment for head and neck cancer includes chemotherapy with cisplatin, docetaxel and 5‑fluorouracil (5‑FU) and the response rates to these drugs in patients is 60‑80%. The present study aimed to generate head and neck cancer triple drug‑resistant cell lines in an effort towards elucidating the mechanisms underlying chemoresistance and providing a resourceful tool for drug design. Using two head and neck squamous cell carcinoma cell lines, Hep‑2 (larynx) and CAL‑27 (oral cavity), the present study sequentially exposed these cells to increasing concentrations of the combination of docetaxel, cisplatin and 5‑FU (TPF) to generate triple drug‑resistant cells, termed Hep‑2 TPF resistant (TPFR) and CAL‑27 TPFR. The effect of the drug treatments on the cell viability, apoptosis, cell cycle and the expression of genes associated with multidrug resistance were analyzed in the parental cells and drug‑resistant counterparts. The Hep‑2 TPFR and CAL‑27 TPFR cells exhibited a higher resistance index (RI≥2) compared with that of the parental cells. Cell cycle analysis revealed a decreased number of TPFR cells in G0/G1 phase (P<0.05) and a corresponding accumulation of cells in G2/M phase. A reduced degree of apoptosis in these cells (Hep‑2, 33 vs 20%, P=0.003; and CAL‑27, 18 vs 9.7%) was complemented by an increased expression of genes involved in drug resistance, including MDR1, MRP2, ERCC1, CTR, survivin and thymidylate synthase. The present study, therefore, established two multi drug‑resistant head and neck squamous cell carcinoma cell lines and characterized these cells on a cellular and molecular level. Development of these tools accentuates their requirement in the field of drug discovery and in mechanistic studies elucidating the underlying mechanisms of drug resistance.

View Figures

View References

1	Kogashiwa Y, Sakurai H, Kimura T and Kohno N: Docetaxel suppresses invasiveness of head and neck cancer cells in vitro. Cancer Sci. 101:1382–1386. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pignon JP, Syz N, Posner M, et al: Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs. 15:331–340. 2004. View Article : Google Scholar : PubMed/NCBI
3	Salama JK, Seiwert TY and Vokes EE: Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 25:4118–4126. 2007. View Article : Google Scholar : PubMed/NCBI
4	Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
5	Bourhis J, Le Maître A, Baujat B, Audry H and Pignon JP: Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol. 19:188–194. 2007. View Article : Google Scholar : PubMed/NCBI
6	Brockstein B, Haraf DJ, Rademaker AW, et al: Patterns of failure, prognostic factors and survival in loco-regionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 15:1179–1186. 2004. View Article : Google Scholar : PubMed/NCBI
7	Stordal B, Hamon M, McEneaney V, et al: Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One. 7:e407172012. View Article : Google Scholar : PubMed/NCBI
8	Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H and Seiden MV: CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol. 63:681–689. 2009. View Article : Google Scholar
9	Wahl H, Tan L, Griffith K, Choi M and Liu JR: Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol. 105:104–112. 2007. View Article : Google Scholar
10	Duan Z, Duan Y, Lamendola DE, et al: Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 9:2778–2785. 2003.PubMed/NCBI
11	Husain A, He G, Venkatraman ES and Spriggs DR: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58:1120–1123. 1998.PubMed/NCBI
12	Hill BT, Whelan RD, Shellard SA, McClean S and Hosking LK: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs. 12:169–182. 1994. View Article : Google Scholar : PubMed/NCBI
13	Plumb JA, Luo W and Kerr DJ: Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer. 67:728–733. 1993. View Article : Google Scholar : PubMed/NCBI
14	Yamano Y, Uzawa K, Saito K, et al: Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010. View Article : Google Scholar
15	Aoki K, Ogawa T, Ito Y and Nakashima S: Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep. 11:375–379. 2004.PubMed/NCBI
16	Gosepath EM, Eckstein N, Hamacher A, et al: Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer. 123:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
17	Gu F, Ma Y, Zhang Z, et al: Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep. 23:671–676. 2010.PubMed/NCBI
18	Li L, Jiang AC, Dong P, Wan Y and Yu ZW: The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol. Otolaryngol Head Neck Surg. 137:659–664. 2007. View Article : Google Scholar : PubMed/NCBI
19	Mizumachi T, Suzuki S, Naito A, et al: Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene. 27:831–838. 2008. View Article : Google Scholar :
20	Yasumatsu R, Nakashima T, Uryu H, et al: The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells. Oral Oncol. 45:141–147. 2009. View Article : Google Scholar
21	Beck A, Etienne MC, Chéradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 30A:1517–1522. 1994. View Article : Google Scholar : PubMed/NCBI
22	Yoo GH, Lin HS, Iskander AJ, et al: Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Laryngoscope. 115:1938–1946. 2005. View Article : Google Scholar : PubMed/NCBI
23	Coley HM: Development of drug-resistant models. Methods Mol Med. 88:267–273. 2004.
24	Murakami H, Ito S, Tanaka H, Kondo E, Kodera Y and Nakanishi H: Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis. Anticancer Res. 33:4299–4307. 2013.PubMed/NCBI
25	Rao GH, Liu HM, Li BW, et al: Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. Acta Pharmacol Sin. 34:793–804. 2013. View Article : Google Scholar : PubMed/NCBI
26	Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL and Ford CE: The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 13:1742013. View Article : Google Scholar : PubMed/NCBI
27	Takahashi K, Tanaka M, Inagaki A, et al: Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. Int J Oncol. 43:1985–1991. 2013.PubMed/NCBI
28	Maseki S, Ijichi K, Tanaka H, et al: Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer. 106:1196–1204. 2012. View Article : Google Scholar : PubMed/NCBI
29	Negoro K, Yamano Y, Fushimi K, et al: Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol. 30:1325–1332. 2007.PubMed/NCBI
30	Nakamura M, Nakatani K, Uzawa K, et al: Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol Rep. 14:1281–1286. 2005.PubMed/NCBI
31	Pinto AL and Lippard SJ: Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta. 780:167–180. 1985.PubMed/NCBI
32	Owellen RJ, Hartke CA, Dickerson RM and Hains FO: Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 36:1499–1502. 1976.PubMed/NCBI
33	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
34	Loehrer PJ Sr, Einhorn LH, Williams SD, Hui SL, Estes NC and Pennington K: Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. Cancer Treat Rep. 69:1359–1363. 1985.PubMed/NCBI
35	Qin H, Luo J, Zhu YP, Xie HL, Yang WQ and Lei WB: Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis. PLoS One. 7:e515262012. View Article : Google Scholar : PubMed/NCBI
36	Hitt R, Paz-Ares L, Brandariz A, et al: Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol. 13:1665–1673. 2002. View Article : Google Scholar : PubMed/NCBI
37	Hussain M, Salwen W, Kucuk O and Ensley J: Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Semin Oncol. 24:S19–43. S19–45. 1997.
38	Choi YJ, Chung J, Shin HJ, et al: Induction chemotherapy of docetaxel and Cisplatin for the elderly patients with squamous cell carcinoma of the head and neck. Cancer Res Treat. 39:1–5. 2007. View Article : Google Scholar : PubMed/NCBI
39	Adamo V, Ferraro G, Pergolizzi S, et al: Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 40:525–531. 2004. View Article : Google Scholar : PubMed/NCBI
40	Liu YL, Zhang GQ, Yang Y, Zhang CY, Fu RX and Yang YM: Genistein induces G2/M arrest in gastric cancer cells by increasing the tumor suppressor PTEN expression. Nutr Cancer. 65:1034–1041. 2013. View Article : Google Scholar : PubMed/NCBI
41	Ismail IA, Kang KS, Lee HA, Kim JW and Sohn YK: Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol. 575:12–20. 2007. View Article : Google Scholar : PubMed/NCBI
42	Nawab A, Thakur VS, Yunus M, Ali Mahdi A and Gupta S: Selective cell cycle arrest and induction of apoptosis in human prostate cancer cells by a polyphenol-rich extract of Solanum nigrum. Int J Mol Med. 29:277–284. 2012.
43	Wang WZ, Cheng J, Luo J and Zhuang SM: Abrogation of G2/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis. FEBS Lett. 582:2689–2695. 2008. View Article : Google Scholar : PubMed/NCBI
44	Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA and O’Connor PM: UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 88:956–965. 1996. View Article : Google Scholar : PubMed/NCBI
45	Sun XC, Cheng HY, Deng YX, Shao RG and Ma J: Tetrandrine: a potent abrogator of G2 checkpoint function in tumor cells and its mechanism. Biomed Environ Sci. 20:495–501. 2007.
46	Chappell J and Dalton S: Altered cell cycle regulation helps stem-like carcinoma cells resist apoptosis. BMC Biol. 8:632010. View Article : Google Scholar : PubMed/NCBI
47	Pratt MA, Niu MY and Renart LI: Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells. Apoptosis. 11:589–605. 2006. View Article : Google Scholar : PubMed/NCBI
48	Nestal de Moraes G, Silva KL, Vasconcelos FC and Maia RC: Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells. Oncol Rep. 25:1613–1619. 2011.PubMed/NCBI
49	Ohishi Y, Oda Y, Uchiumi T, et al: ATP-binding cassette super-family transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res. 8:3767–3775. 2002.PubMed/NCBI
50	Lee J, Jiffar T and Kupferman ME: A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma. PLoS One. 7:e302462012. View Article : Google Scholar : PubMed/NCBI
51	Köberle B, Ditz C, Kausch I, Wollenberg B, Ferris RL and Albers AE: Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. Int J Oncol. 36:1277–1284. 2010.PubMed/NCBI
52	Hayes M, Lan C, Yan J, et al: ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res. 31:4135–4139. 2011.PubMed/NCBI
53	Song IS, Savaraj N, Siddik ZH, et al: Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 3:1543–1549. 2004.
54	Holzer AK, Samimi G, Katano K, et al: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 66:817–823. 2004. View Article : Google Scholar : PubMed/NCBI
55	Peters GJ, Backus HH, Freemantle S, et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
56	Wong NA, Brett L, Stewart M, et al: Nuclear thymidylate synthase expression, p53 expression and 5-FU response in colorectal carcinoma. Br J Cancer. 85:1937–1943. 2001. View Article : Google Scholar : PubMed/NCBI
57	Saiki Y, Ogawa T, Shiga K, Sunamura M, Kobayashi T and Horii A: A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane. Int J Otolaryngol. 2011:5218522011. View Article : Google Scholar : PubMed/NCBI
58	Tamatani T, Ferdous T, Takamaru N, et al: Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells. Int J Oncol. 41:1148–1156. 2012.PubMed/NCBI